<em>CREB1</em> acts via the miR‑922/<em>ARID2</em> axis to enhance malignant behavior of liver cancer cells

Liu,Xinyu; Zhang,Hao; Zhou,Pengcheng; Yu,Yaqun; Zhang,Haoye; Chen,Limin; Gong,Jian; Liu,Zhenguo

doi:10.3892/or.2021.8030

CREB1 acts via the miR‑922/ARID2 axis to enhance malignant behavior of liver cancer cells

Authors:
- Xinyu Liu
- Hao Zhang
- Pengcheng Zhou
- Yaqun Yu
- Haoye Zhang
- Limin Chen
- Jian Gong
- Zhenguo Liu
View Affiliations

Affiliations: Department of Infectious Disease, The Third Xiangya Hospital, Central South University, Changsha, Hunan 410013, P.R. China, Department of Nephrology, The Third Xiangya Hospital, Central South University, Changsha, Hunan 410013, P.R. China, Department of Hepatobiliary and Pancreatic Surgery, The Affiliated Hospital of Guilin Medical College, Guilin, Guangxi 541002, P.R. China
Published online on: March 26, 2021 https://doi.org/10.3892/or.2021.8030
Article Number: 79
Copyright: © Liu et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

There is little information on the role of microRNA (miR)‑922 in the malignant behavior of liver cancer. The present study investigated the regulation of miR‑922 expression levels by cAMP response element binding protein 1 (CREB1) in liver cancer tissue, its role in regulating malignant behavior and its potential targets in liver cancer. miR‑922 expression in liver cancer cells and tissue was determined by reverse transcription‑quantitative PCR. The binding of CREB1 to the promoter region of mir‑922 was tested by chromatin immunoprecipitation‑PCR. The predicted AT‑rich interactive domain 2 (ARID2) and fidgetin, microtubule severing factor targets of miR‑922 were characterized by dual luciferase reporter assay. The effects of altered ARID2 expression levels on miR‑922‑enhanced malignant behavior of liver cancer cells were tested. CREB1 bound to the promoter region of miR‑922. Elevated miR‑922 transcripts were inversely associated with ARID2 expression in liver cancer tissue and cells. miR‑922 inhibited ARID2‑regulated luciferase expression and was present in the miR/argonaute RISC catalytic component 2 complex. ARID2 significantly decreased malignant behavior of liver cancer MHCC97L cells. Similarly, ARID2 over‑expression inhibited growth of xenograft liver cancer tumors and decreased miR‑922, Bcl‑2, proliferating cell nuclear antigen, cyclin D1, MMP3 and MMP9 expression and serum VEGF and TNF‑α levels, but enhanced Bax expression levels in tumors. ARID2 over‑expression abrogated malignant behavior promoted by miR‑922 over‑expression and enhanced miR‑922‑decreased malignant behavior of liver cancer cells. CREB induced miR‑922 transcription, which targeted ARID2 to enhance malignant behavior of liver cancer cells, indicating that the CREB1/miR‑922/ARID2 axis may be a potential target for liver cancer treatment.

View Figures

View References

1	Singh AK, Kumar R and Pandey AK: Hepatocellular carcinoma: Causes, mechanism of progression and biomarkers. Curr Chem Genom Transl Med. 12:9–26. 2018. View Article : Google Scholar : PubMed/NCBI
2	Zhu X, Tang Z and Sun HC: Targeting angiogenesis for liver cancer: Past, present, and future. Genes Dis. 7:328–335. 2020. View Article : Google Scholar : PubMed/NCBI
3	Sagnelli E, Potenza N, Onorato L, Sagnelli C, Coppola N and Russo A: Micro-RNAs in hepatitis B virus-related chronic liver diseases and hepatocellular carcinoma. World J Hepatol. 10:558–570. 2018. View Article : Google Scholar : PubMed/NCBI
4	Sengupta S and Parikh ND: Biomarker development for hepatocellular carcinoma early detection: Current and future perspectives. Hepat Oncol. 4:111–122. 2017. View Article : Google Scholar : PubMed/NCBI
5	Rupaimoole R, Calin GA, Lopez-Berestein G and Sood AK: miRNA deregulation in cancer cells and the tumor microenvironment. Cancer Discov. 6:235–246. 2016. View Article : Google Scholar : PubMed/NCBI
6	Shayimu P, Wang JB, Liu L, Tuerdi R, Yu CG and Yusufu A: miR-922 regulates apoptosis, migration, and invasion by targeting SOCS1 in gastric cancer. Kaohsiung J Med Sci. 36:178–185. 2020. View Article : Google Scholar : PubMed/NCBI
7	Liu J, Su Z, Zeng Y, Zhang H, Yang S and Liu G: miR-922 regulates CYLD expression and promotes the cell proliferation of human hepatocellular carcinoma. Oncol Rep. 37:1445–1450. 2017. View Article : Google Scholar : PubMed/NCBI
8	Sevinc ED, Cecener G, Ak S, Tunca B, Egeli U, Gokgoz S, Tolunay S and Tasdelen I: Expression and clinical significance of miRNAs that may be associated with the FHIT gene in breast cancer. Gene. 590:278–284. 2016. View Article : Google Scholar : PubMed/NCBI
9	Abramovitch R, Tavor E, Jacob-Hirsch J, Zeira E, Amariglio N, Pappo O, Rechavi G, Galun E and Honigman A: A pivotal role of cyclic AMP-responsive element binding protein in tumor progression. Cancer Res. 64:1338–1346. 2004. View Article : Google Scholar : PubMed/NCBI
10	Kovach SJ, Price JA, Shaw CM, Theodorakis NG and McKillop IH: Role of cyclic-AMP responsive element binding (CREB) proteins in cell proliferation in a rat model of hepatocellular carcinoma. J Cell Physiol. 206:411–419. 2006. View Article : Google Scholar : PubMed/NCBI
11	Li Y, Fu Y, Hu X, Sun L, Tang D, Li N, Peng F and Fan XG: The HBx-CTTN interaction promotes cell proliferation and migration of hepatocellular carcinoma via CREB1. Cell Death Dis. 10:4052019. View Article : Google Scholar : PubMed/NCBI
12	Oba A, Shimada S, Akiyama Y, Nishikawaji T, Mogushi K, Ito H, Matsumura S, Aihara A, Mitsunori Y, Ban D, et al: ARID2 modulates DNA damage response in human hepatocellular carcinoma cells. J Hepatol. 66:942–951. 2017. View Article : Google Scholar : PubMed/NCBI
13	Marrero JA, Kulik LM, Sirlin CB, Zhu AX, Finn RS, Abecassis MM, Roberts LR and Heimbach JK: Diagnosis, staging, and management of hepatocellular carcinoma: 2018 practice guidance by the American association for the study of liver diseases. Hepatology. 68:723–750. 2018. View Article : Google Scholar : PubMed/NCBI
14	Tellapuri S, Sutphin PD, Beg MS, Singal AG and Kalva SP: Staging systems of hepatocellular carcinoma: A review. Indian J Gastroenterol. 37:481–491. 2018. View Article : Google Scholar : PubMed/NCBI
15	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI
16	Zhu P, Wang Y, Wu J, Huang G, Liu B, Ye B, Du Y, Gao G, Tian Y, He L and Fan Z: LncBRM initiates YAP1 signalling activation to drive self-renewal of liver cancer stem cells. Nat Commun. 7:136082016. View Article : Google Scholar : PubMed/NCBI
17	Wang YW, Chen X, Ma R and Gao P: Understanding the CREB1-miRNA feedback loop in human malignancies. Tumour Biol. 37:8487–8502. 2016. View Article : Google Scholar : PubMed/NCBI
18	Rad R, Rad L, Wang W, Strong A, Ponstingl H, Bronner IF, Mayho M, Steiger K, Weber J, Hieber M, et al: A conditional piggyBac transposition system for genetic screening in mice identifies oncogenic networks in pancreatic cancer. Nat Genet. 47:47–56. 2015. View Article : Google Scholar : PubMed/NCBI
19	Xu J, Li J, Zheng TH, Bai L and Liu ZJ: MicroRNAs in the occurrence and development of primary hepatocellular carcinoma. Adv Clin Exp Med. 25:971–975. 2016. View Article : Google Scholar : PubMed/NCBI
20	Pineau P, Volinia S, McJunkin K, Marchio A, Battiston C, Terris B, Mazzaferro V, Lowe SW, Croce CM and Dejean A: miR-221 overexpression contributes to liver tumorigenesis. Proc Natl Acad Sci USA. 107:264–269. 2010. View Article : Google Scholar : PubMed/NCBI
21	Varnholt H: The role of microRNAs in primary liver cancer. Ann Hepatol. 7:104–113. 2008. View Article : Google Scholar : PubMed/NCBI
22	He XX, Chang Y, Meng FY, Wang MY, Xie QH, Tang F, Li PY, Song YH and Lin JS: MicroRNA-375 targets AEG-1 in hepatocellular carcinoma and suppresses liver cancer cell growth in vitro and in vivo. Oncogene. 31:3357–3369. 2012. View Article : Google Scholar : PubMed/NCBI
23	Liu Y, Chen SH, Jin X and Li YM: Analysis of differentially expressed genes and microRNAs in alcoholic liver disease. Int J Mol Med. 31:547–554. 2013. View Article : Google Scholar : PubMed/NCBI
24	Lee YS and Dutta A: MicroRNAs in cancer. Annu Rev Pathol. 4:199–227. 2009. View Article : Google Scholar : PubMed/NCBI
25	Hu PC, Li K, Tian YH, Pan WT, Wang Y, Xu XL, He YQ, Gao Y, Wei L and Zhang JW: CREB1/Lin28/miR-638/VASP interactive network drives the development of breast cancer. Int J Biol Sci. 15:2733–2749. 2019. View Article : Google Scholar : PubMed/NCBI
26	Hodges C, Kirkland JG and Crabtree GR: The many roles of BAF (mSWI/SNF) and PBAF complexes in cancer. Cold Spring Harb Perspect Med. 6:a0269302016. View Article : Google Scholar : PubMed/NCBI
27	Linhares AC, Stupka JA, Ciapponi A, Bardach AE, Glujovsky D, Aruj PK, Mazzoni A, Rodriguez JA, Rearte A, Lanzieri TM, et al: Burden and typing of rotavirus group A in Latin America and the Caribbean: Systematic review and meta-analysis. Rev Med Virol. 21:89–109. 2011. View Article : Google Scholar : PubMed/NCBI
28	Zhao H, Wang J, Han Y, Huang Z, Ying J, Bi X, Zhao J, Fang Y, Zhou H, Zhou J, et al: ARID2: A new tumor suppressor gene in hepatocellular carcinoma. Oncotarget. 2:886–891. 2011. View Article : Google Scholar : PubMed/NCBI
29	You J, Yang H, Lai Y, Simon L, Au J and Burkart AL: AT-rich interactive domain 2, p110α, p53, and β-catenin protein expression in hepatocellular carcinoma and clinicopathologic implications. Hum Pathol. 46:583–592. 2015. View Article : Google Scholar : PubMed/NCBI
30	Zhang L, Wang W, Li X, He S, Yao J, Wang X, Zhang D and Sun X: MicroRNA-155 promotes tumor growth of human hepatocellular carcinoma by targeting ARID2. Int J Oncol. 48:2425–2434. 2016. View Article : Google Scholar : PubMed/NCBI
31	Wang Y, Chang W, Chang W, Chang X, Zhai S, Pan G and Dang S: MicroRNA-376c-3p facilitates human hepatocellular carcinoma progression via repressing AT-rich interaction domain 2. J Cancer. 9:4187–4196. 2018. View Article : Google Scholar : PubMed/NCBI
32	Yu P, Wu D, You Y, Sun J, Lu L, Tan J and Bie P: miR-208-3p promotes hepatocellular carcinoma cell proliferation and invasion through regulating ARID2 expression. Exp Cell Res. 336:232–241. 2015. View Article : Google Scholar : PubMed/NCBI
33	Liu Q, Yang P, Tu K, Zhang H, Zheng X, Yao Y and Liu Q: TPX2 knockdown suppressed hepatocellular carcinoma cell invasion via inactivating AKT signaling and inhibiting MMP2 and MMP9 expression. Chin J Cancer Res. 26:410–417. 2014.PubMed/NCBI